kontroversi hmam jaringAN YG DI kombinasi

DG darah perifer untuk memantau metastasis

yg bagus: kuantitatif--> memantau perubahan.
kualitatif --> tidak bisa melihat perubahan
STUDI AWAL

Aristizábal-Pachón AF 2015 Detection of human mammaglobin A mRNA in peripheral

blood of breast cancer patients before treatment and association with metastasis. The
presence of MGA DI DARAH was significantly associated with presence of metastasis and age
at onset after 60 years.

The presence of MGA mRNA in peripheral blood displayed a sensitivity of 38.2%, specificity of
100.0%, positive predictive value (PPV) of 100.0%, and negative predictive value (NPV) of
61.8% as a breast cancer marker.

Radwan WM 2013 evaluate the value of peripheral blood mammaglobin (MG) gene expression
for diagnosis and prediction of metastasis in breast cancer patients. MG expression was detected
in 16/32 (50%) breast cancer patients but not in patients with benign lesions or healthy
participants. During the 34 months of follow up, five more MG-positive patients showed
metastatic lesions and none of the MG negative patients who were followed up developed
metastasis.

The study suggests blood MG expression is a specific molecular marker for detection of occult
mammary carcinoma cells of patients with operable breast cancer. It might be of value as a
predictor of subsequent metastasis. Large-scale studies and longer follow-up periods are needed.

Hu YY 2017 Mammaglobin A expression in peripheral blood (PB) of breast carcinoma patients

has been evaluated by various studies, but the findings have been inconsistent. This meta-
analysis aimed to clarify the prognostic value of mammaglobin A in the PB of breast carcinoma
patients and define its relationships with clinicopathological features.
The results indicated that plasma mammaglobin A expression was a predictor of poor
prognosis for breast carcinoma patients, with an HR of 2.08 (95% CI=1.48–2.91; P<0.0001)
for overall survival.
Moreover, plasma mammaglobin A was significantly associated with lymph node metastasis
(OR=2.00; 95% CI=1.17–3.45; P=0.01) and advanced tumor stage (OR=3.01; 95% CI=1.57–
5.77; P=0.0009) in breast carcinoma patients. .

However, the results revealed that plasma mammaglobin A was not significantly associated
with tumor size (OR=1.29; 95% CI=0.46–3.66; P=0.63), tumor differentiation (OR=0.99; 95%
CI=0.63–1.57; P=0.97), menopausal status
(OR=0.75; 95% CI=0.48–1.18; P=0.22), estrogen receptor status (OR=0.78; 95% CI=0.44–
1.36; P=0.38), progesterone receptor status (OR=0.76; 95% CI=0.57–1.02; P=0.07), or human
epidermal growth factor receptor 2 status (OR=1.12; 95% CI=0.78–1.59; P=0.54).

In conclusion, the results demonstrate that positive plasma mammaglobin A expression might
serve as a biomarker of poor prognosis for breast carcinoma patients.

Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-

analysis 

Kaidi Mikhitarian 2008